Personalized cardiac imaging approach for women with early breast cancer on HER2 therapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study examines whether a risk-stratified imaging strategy can safely reduce routine echocardiograms without compromising early detection of cardiotoxicity during about one year of HER2-targeted therapy. Eligible participants are women aged 18-79 with HER2-positive breast cancer and preserved baseline heart function, at Rochester's Wilmot Cancer Center. The study uses echocardiography as the primary imaging modality, guided by individual cardiovascular risk factors. Exclusion criteria include prior heart disease, significant rhythm or valve issues, high cumulative anthracycline exposure, and pregnancy. The lead sponsor is the University of Rochester, with enrollment at a single site.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Female sex, age 18-79 years.
* Histologically confirmed HER2-positive BC scheduled for ≈12 months of adjuvant HER2-TT
* Baseline LVEF ≥ 55 % by 2-D echocardiography.
* Ability to provide informed consent.

Exclusion Criteria:

* Prior HF, myocardial infarction, or cardiomyopathy.
* Atrial fibrillation or significant valvular heart disease.
* Cumulative anthracycline dose ≥ 250 mg/m².
* Pregnancy or lactation.
* Inability to comply with study procedures.

Where it's running

• Wilmot Cancer Center
  Rochester, New York, United States Recruiting

Study contacts

• Study coordinator: Kaily LaForce
• Email: kaily_laforce@urmc.rochester.edu
• Phone: 585-274-2808

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Magtrace bracketing to guide lumpectomy and sentinel node biopsy

  This study tests whether Magtrace bracketing can help accurately locate the tumor and sentinel lymph node during breast-conserving surgery.

  Recruiting King Faisal Specialist Hospital & Research Center · Madinah · NCT07844473

• Oncoliq blood test for early detection of breast cancer

  This project will test whether a blood-based miRNA panel (the Oncoliq Test) can detect early breast cancer in adults 40–70 by comparing newly diagnosed, untreated patients with cancer-free controls.

  Recruiting Oncoliq US Inc · Buenos Aires, Buenos Aires · NCT07331506

• Disitamab Vedotin for treating hormone receptor positive, HER2-low metastatic breast cancer

  This study is testing a new drug called Disitamab Vedotin to see if it can help people with hormone receptor positive, HER2-low metastatic breast cancer who haven't responded to standard treatments.

  Recruiting at 3 sites Phase 3 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong and 2 other locations · NCT05904964

• Phase II test of SHR-A1811 for ultra-low HER2 advanced breast cancer

  This phase II trial tests SHR-A1811 in women with advanced breast cancer and ultra-low HER2 expression who have had 1-2 prior therapies.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT07817082

• Using 18F-HER2 Affibody PET Imaging for HER2-Positive Breast Cancer

  This study is testing a new imaging method using a special protein to see if it can help doctors better diagnose and monitor breast cancer that has the HER2 protein.

  Recruiting The Affiliated Hospital of Qingdao University · Qingdao, Shandong · NCT06916637

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.